Drugs / Meningococcal Diphtheria Toxoid Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01890759 | Jun 2013 → Apr 2016 | meningitis, meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Meningococcal Diphtheria Toxoid Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01890759 ↗ |
| Modality | Vaccine | “Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®)” NCT01890759 ↗ |
| Route | Intramuscular | “0.5 mL, Intramuscular” NCT01890759 ↗ |